About: Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application
Creator	Zhang, Jing Coccia, Eliana Chopp, Michael Cruciani, Melania Garaci, Enrico Giacomini, Elena Rizzo, Fabiana Severa, Martina Etna, Paola
Source	Elsevier; Medline; PMC
abstract	Background: Multiple sclerosis (MS) afflicts more than 2.5 million individuals worldwide and this number is increasing over time. Within the past years, a great number of disease-modifying treatments have emerged; however, efficacious treatments and a cure for MS await discovery. Thymosins, soluble hormone-like peptides produced by the thymus gland, can mediate immune and non-immune physiological processes and have gained interest in recent years as therapeutics in inflammatory and autoimmune diseases. Methods: Pubmed was searched with no time constraints for articles using a combination of the keywords “thymosin/s” or “thymus factor/s” AND “multiple sclerosis”, mesh terms with no language restriction. Results: Here, we review the state-of-the-art on the effects of thymosins on MS and its experimental models. In particular, we describe what is known in this field on the roles of thymosin-α1 (Tα1) and -β4 (Tβ4) as potential anti-inflammatory as well as neuroprotective and remyelinating molecules and their mechanisms of action. Conclusion: Based on the data that Tα1 and Tβ4 act as anti-inflammatory molecules and as inducers of myelin repair and neuronal protection, respectively, a possible therapeutic application in MS for Tα1 and Tβ4 alone or combined with other approved drugs may be envisaged. This approach is reasonable in light of the current clinical usage of Tα1 and data demonstrating the safety, tolerability and efficacy of Tβ4 in clinical practice.
has issue date	2018-10-02(xsd:dateTime)
bibo:doi	10.1016/j.msard.2018.09.035
bibo:pmid	30317071
has license	no-cc
sha1sum (hex)	8c55bcbbc026105e30552c1c955cabef0bffcdba
schema:url	https://doi.org/10.1016/j.msard.2018.09.035
resource representing a document's title	Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application
has PubMed Central identifier	PMC7104151
has PubMed identifier	30317071
schema:publication	Mult Scler Relat Disord
resource representing a document's body	covid:8c55bcbbc026105e30552c1c955cabef0bffcdba#body_text
is schema:about of	named entity 'BASIC' named entity 'THYMOSINS' named entity 'Thymosins' named entity 'application' named entity 'CLINICAL APPLICATION' named entity 'MOVING' named entity 'MULTIPLE SCLEROSIS' named entity 'ITS' named entity 'EXPERIMENTAL MODELS' named entity 'polypeptide' named entity 'remyelination' named entity 'CD24' named entity 'anti-inflammatory' named entity 'remyelination' named entity 'isoelectric focusing' named entity 'down-regulation' named entity 'miRNAs' named entity 'autoimmune diseases' named entity 'microglia' named entity 'arthritis, rheumatoid' named entity 'cell compartment' named entity 'inflammation' named entity 'long-lasting' named entity 'TLR7' named entity 'regulatory B cells' named entity 'CD27' named entity 'demyelination' named entity 'peripheral nerves' named entity 'plasma cells' named entity 'Nave' named entity 'chronic inflammatory' named entity 'motility' named entity 'bone marrow transplant' named entity 'tryptophan' named entity 'prophylactic treatment' named entity 'reduce inflammation' named entity 'chromosome' named entity 'CD27' named entity 'neurons' named entity 'human body' named entity 'up-regulated' named entity 'proteolipid protein' named entity 'angiogenesis' named entity 'axonal regeneration' named entity 'cell motility' named entity 'cell differentiation' named entity 'adjuvant' named entity 'anti-CD20' named entity 'phenotype' named entity 'direct action' named entity 'guinea pigs' named entity 'CD19' named entity 'corpus callosum' named entity 'autoimmune diseases' named entity 'ortholog' named entity 'miR-146a' named entity 'CNS' named entity 'chronic inflammation' named entity 'IgG' named entity 'peripheral circulation' named entity 'extracellular' named entity 'neurons' named entity 'autoimmune diseases' named entity 'EAE' named entity 'traumatic brain injury' named entity 'arthritis' named entity 'C-terminus' named entity 'cell lineage' named entity 'aromatic amino acids' named entity 'PLP' named entity 'EAE' named entity 'endogenous' named entity 'thymosin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software